Angle Regulatory News (AGL)

17 Oct 2005 07:01

Angle PLC17 October 2005 For Immediate Release 17 October 2005 ANGLE plc Senior appointments to Ventures (US) team and opening of Philadelphia office ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology is pleased to announce two senior appointmentsin the United States within its Ventures (US) team: Dr David Counts, asAssociate Director-Ventures, and James Goldberg as Vice President. The two willlead the commercialisation of early-stage technologies in life sciences, medicaldevices and other healthcare technologies and services from universities,national laboratories, and corporations. In conjunction with these appointments, ANGLE also announces the opening of itsnew office in Philadelphia. David Counts joins ANGLE from the Ben Franklin Technology Partners where he wasDirector of Life Sciences helping develop the Innovation Partnership as well asbeing responsible for obtaining corporate sponsors for the NanotechnologyInstitute. Prior to this, he helped evaluate technologies for BTG, was aco-founder and Chief Scientific Officer of a life sciences start-up and workedwith Eli Lily, Marion Merrill Dow and the Gillette Research Institute. He willwork closely with the technology transfer staff at the Philadelphia areauniversities to help identify suitable technologies for commercialisation and tocreate start-up ventures with the Ben Franklin Technology Partnership and otherprivate investment organisations in the region. James Goldberg previously worked with Stanford Research Institute and theLawrence Livermore National Laboratory to create new spin-out companies in themedical device area. He was a Principal of Nextera, Inc, a business started byLarry Ellison, co-founder of Oracle, and was founder of an information businessservices provider, Smart Analyst, based in New York and New Delhi. Additionally,he was a Director of R2 Medical Systems (NASDAQ) and has been a Principal withthe PA Consulting Group working with a variety of international companies suchas Johnson & Johnson, Pfizer, Apple, IBM and Proctor & Gamble. Commenting on the appointments, Rob Kornblum, Managing Director of ANGLEVentures (US) said: "The addition of David and James adds significantly to our life sciences andhealthcare expertise. They both bring a solid understanding of how tocommercialise university, national laboratory, and corporate intellectualproperty in addition to extensive technical skills. We are excited to have themon board." Andrew Newland, Chief Executive of ANGLE said: "This is a further step in the planned expansion of our ventures activity in theUnited States exploiting the strong pipeline of opportunities, which we havedeveloped since establishing ANGLE in the United States six years ago." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief Executive Rob Kornblum, MD Ventures (US) +1 703-748-7133 Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange